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Although the insulin-secreting capacity of the sulphonylurea compounds is accepted, it still remains to be settled whether the antidiabetic effect of the longterm administration of these drugs is solely due to their ability to stimulate the beta cell. Indeed, several investigators have reported a diminished insulin response to various stimuli after chronic sulphonylurea administration in man as well as in laboratory animals [1, 2, 3, 4] . This topic has been reviewed by Feldman and Lebovitz [5] .
In 1969 Samols and associates [6] , working with an animal model (Peking ducks), humans, and isolated rat pancreas described a glucagon-lowering effect of tolbutamide, an action which would obviously be an important factor in explaining the hypoglyeaemie effect of the sulphonylureas. In the present work we have studied the effects of a seven-day course of treatment with glipizide (a new and potent sulphonylurea) [7] and with glibenclamide on basal glueagon levels and on the secretory response of the alpha cell to an arginine challenge in two different groups of normal subjects. It was found that neither glipizide nor glibenelamide significantly affected the secretion of glucagon.
Materials and Methods
Young, healthy, non-obese volunteers of both sexes, with no clinical history of diabetes in their families, were selected for our study. All were students at the Universidad Aut6noma de Madrid and had been informed of the purpose and nature of the experiments. * Presented at the Eighth Annum Meeting of the European Association for the Study of Diabetes, September 7, 1972, Madrid, Spain. This work has been in part supported by I.N.P. grant 12-071-72.
Volunteers had been instructed to follow a diet containing at least 250 g of carbohydrates daily for three days before the start of the experiments and during the period of sulphonylurea treatment. One group of seven subjects was given glipizide (N-4-[fi-(5-Methylpyrazine-2-carboxamido) -ethyl]-benzene -sulphonyl} -N'-cyclohexyl-urea) in a single dose of 10 mg daily before the mid-day meal. The second group, of six subjects, was given glibenelamide at the same dose level 1. The drug regimen was followed for seven days. Each individual served as his own control.
Volunteers reported to the laboratory between 9 : 00 and 10:00 a.m. after an overnight fast. Tests were carried out with the subjects in a recumbent position. For sampling, an indwelling butterfly needle connected to a stopcock was placed in an anteeubital vein and kept patent with a 0.1 ~ hcparin solution. In the other arm, a similar set-up was applied for the administration of the arginine load. Arginine monohydrochloride in a 20~o solution (Arginina, Hermes), was injected as a dose of 468 mg per kg of body weight over a ten-minute period. The subjects were allowed to relax for twenty minutes before collection of the first control sample.
Blood samples (10 ml) were drawn at ten-minute intervals throughout the test. For glucose and insulin measurements, 5 ml of blood were placed in chilled tubes containing EDTA; another 5 ml for glueagon analysis were collected in chilled tubes containing EDTA and 2500 U of kallikrein-trypsin inhibitor (Trasylol, Bayer) in a volume of 0.5 ml. The blood was promptly centrifuged at 4~ and the plasma was stored at --20~ nntil the time of assay. Assays were performed within two weeks of the date of the experiments. All samples were tested in duplicate. Plasma 1 The drugs used in this study were kindly supplied by Dr. M. Usano, Pfizer, Spain.
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glucose was determined by moans of ~ commercial glucose-oxidase preparation (Biochemica Test Combination, Boehringer Mannheim GmbH). Insulin was measured by radioimmunoassay using a charcoal separation method [8] . Glucagon was assayed radioimmunologically [9] with an antiserum (30K) highly specific for pancreatic glucagon (kindly supplied by Dr. Roger H. Unger). Our glucagon analysis allows measurement of 25 pg/ml above zero with 95% confidence and we have been able to detect a decline of 37 picogram/ml from the basal values in other studies [10] .
Statistical processing of the data was performed by conventional methods.
Results
Glipizide-Treated Group. In Fig. 1 are represented the mean glucagon, insulin and glucose curves for the group of subjects treated with glipizide.
ments. The sample taken at 90 min showed a difference (34 pg/ml) with a P value of less than 0.05 but, since this was the only point of the thirteen studied in which a statistically significant difference could be detected, we regard it as a random finding.
With the exception of a 3 ~zU/ml change (P < 0.005) above control at the --10 rain baseline point, there is no significant difference between the pro and posttreatment insulin curves.
After treatment with glipizide, the entire glucose curve lay above the control values; the differences being significant in the three baseline points (P ~ 0.01), at 10, 20, and 30 min (P < 0.05), and at 70, 80, 90, and 100 rain (P <0.00i).
Glibenelamide-Treated Group. In this group, (Fig. 2) as in the proceeding one, the pro and post-treatment glucagon levels before and after the arginine load overlapped. The plasma insulin concentrations were not significantly affected by glibenclamide pretreatmont. Although, as in the glipizide experiments, the post-treatment glucose curve was elevated above the control, the elevation was less marked and without statistical significance.
Discussion
In an attempt to simulate the true elinicM situation in which the patient continues sulphonylurea treatment over a long period of time, we have employed a seven-day course of administration of the drugs rather than giving an isolated dose.
The data here reported show that neither glipizide nor glibenclamide has any influence on basal glucagon levels and alpha cell responsiveness to arginine in normal subjects. This does not support the concept that the sulphonylureas might, in part, exert their hypoglyeaemie effect via the alpha cell. Likewise, Pek et al. [ ill were unable to demonstrate any significant modification of basal glucagon levels and amino acidinduced glucagon secretion after i.v. tolbutamide or oral chlorpropamide in healthy volunteers. Similar results were obtained by Aguilar-Parada et al. [12] injecting one dose of glibenclamide in dogs. Buchanan et al. in isolated rat pancreatic islets [13] and Chesney and Schofield in mouse islets [14] also failed to demonstrate any change in the secretion of glueagon with tolbutamide. Contrary to these "in vitro" studies, Laube et al. [15] , working in perfused rat pancreas, and Iversen [16] , working in perfused canine pancreas, have reported an inhibitory effect of tolbutamide on glucagon release. However, our results do not exclude the possibility that sulphonylureas could induce a reduction of the hyperglueagonaemia seen in diabetics [9] , as a consequence of the amelioration of the disturbed metabolic state.
Concerning insulin secretion, there was no obvious difference between the pre and the post-treatment mean curves with either of the two sulphonylureas tested. There was great variability in the response to arginine; in some cases there was a slight increase and in others, a frank decrease. The latter finding could be due to a relative exhaustion of the beta cell occurring in normal subjects after over-stimulation with these drugs. A consequence of this exhaustion of the beta cell would be an elevation of the glycaemia. This hyperglycaemia would, in turn, further stimulate insulin secretion, the net effect of which would be a normalization of insulin levels.
